Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  04:00PM ET
196.52
Dollar change
+1.02
Percentage change
0.52
%
IndexS&P 500 P/E22.32 EPS (ttm)8.81 Insider Own0.18% Shs Outstand146.80M Perf Week-2.32%
Market Cap28.84B Forward P/E12.12 EPS next Y16.22 Insider Trans-1.46% Shs Float146.44M Perf Month16.07%
Enterprise Value31.68B PEG2.91 EPS next Q3.04 Inst Own93.44% Short Float3.20% Perf Quarter21.70%
Income1.29B P/S3.03 EPS this Y3.53% Inst Trans1.41% Short Ratio2.36 Perf Half Y45.64%
Sales9.53B P/B1.58 EPS next Y2.50% ROA4.50% Short Interest4.69M Perf YTD11.67%
Book/sh124.37 P/C7.56 EPS next 5Y4.16% ROE7.39% 52W High202.41 -2.91% Perf Year41.94%
Cash/sh26.00 P/FCF14.06 EPS past 3/5Y-25.04% -18.74% ROIC5.21% 52W Low110.04 78.60% Perf 3Y-32.34%
Dividend Est.- EV/EBITDA9.90 Sales past 3/5Y0.35% -5.06% Gross Margin66.60% Volatility3.35% 3.22% Perf 5Y-29.32%
Dividend TTM- EV/Sales3.32 EPS Y/Y TTM-21.29% Oper. Margin25.39% ATR (14)6.08 Perf 10Y-13.70%
Dividend Ex-Date- Quick Ratio2.03 Sales Y/Y TTM2.88% Profit Margin13.56% RSI (14)64.15 Recom2.31
Dividend Gr. 3/5Y- - Current Ratio2.68 EPS Q/Q-118.25% SMA208.58% Beta0.14 Target Price208.77
Payout0.00% Debt/Eq0.36 Sales Q/Q-6.71% SMA509.94% Rel Volume0.68 Prev Close195.50
Employees7500 LT Debt/Eq0.36 EarningsFeb 06 BMO SMA20031.68% Avg Volume1.99M Price196.52
IPOSep 17, 1991 Option/ShortYes / Yes EPS/Sales Surpr.22.45% 3.48% Trades Volume1,352,247 Change0.52%
Date Action Analyst Rating Change Price Target Change
Feb-09-26Reiterated H.C. Wainwright Buy $194 → $228
Jan-07-26Resumed UBS Neutral $185
Dec-10-25Downgrade HSBC Securities Hold → Reduce $143
Nov-06-25Upgrade Stifel Hold → Buy $202
Sep-25-25Initiated Jefferies Buy $190
Jul-21-25Resumed Truist Hold $142
Apr-28-25Downgrade HSBC Securities Buy → Hold $118
Apr-04-25Downgrade Argus Buy → Hold
Feb-11-25Initiated Bernstein Mkt Perform $160
Jan-02-25Downgrade Piper Sandler Overweight → Neutral $315 → $138
Feb-13-26 11:22AM
10:27AM
09:57AM
06:00AM
12:36AM
11:41PM Loading…
Feb-12-26 11:41PM
Feb-11-26 05:00PM
04:47AM
Feb-08-26 09:00PM
05:31PM
Feb-07-26 12:31AM
Feb-06-26 07:43PM
04:02PM
03:48PM
11:30AM
11:15AM Loading…
11:15AM
11:12AM
10:33AM
10:29AM
10:10AM
09:42AM
09:30AM
08:59AM
08:59AM
07:35AM
07:17AM
07:15AM
07:03AM
06:09AM
05:39AM
05:35AM Loading…
05:35AM
Feb-05-26 07:00PM
04:27AM
Feb-04-26 10:02PM
04:01PM
07:30AM
04:36AM
Feb-03-26 02:57PM
10:00AM
07:56AM
Feb-01-26 07:47AM
Jan-30-26 10:00AM
Jan-29-26 04:09PM
08:53AM
06:06AM
Jan-28-26 12:47PM
07:30AM
Jan-25-26 06:30PM
06:30PM
Jan-22-26 09:00AM
Jan-20-26 08:28AM
Jan-14-26 08:46AM
Jan-13-26 11:45AM
09:11AM
03:02AM
Jan-12-26 11:05AM
Jan-11-26 11:05PM
02:00PM
Jan-10-26 02:57PM
Jan-07-26 01:01PM
Jan-05-26 08:00PM
01:52PM
07:02AM
Jan-02-26 07:44AM
Dec-29-25 10:03AM
Dec-28-25 03:00AM
Dec-22-25 11:20AM
Dec-21-25 10:31PM
Dec-19-25 11:50AM
Dec-17-25 05:13PM
01:40PM
Dec-16-25 01:15PM
Dec-15-25 12:15PM
10:05AM
09:11AM
07:03AM
Dec-13-25 11:04AM
Dec-12-25 08:21PM
04:53AM
Dec-10-25 11:31PM
12:40PM
11:13AM
09:40AM
09:09AM
08:36AM
04:47AM
Dec-08-25 06:30PM
01:53PM
03:37AM
Dec-05-25 11:30AM
09:56AM
09:00AM
Dec-03-25 06:10PM
11:30AM
07:26AM
Dec-02-25 04:40PM
Dec-01-25 07:30AM
07:30AM
Nov-27-25 07:30PM
Nov-26-25 05:30AM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Viehbacher ChristopherPresident and CEOFeb 06 '26Option Exercise0.0024,461036,548Feb 10 05:06 PM
Singhal PriyaHead of DevelopmentFeb 06 '26Option Exercise0.006,900012,115Feb 10 05:05 PM
Singhal PriyaHead of DevelopmentFeb 09 '26Sale199.832,660531,5488,043Feb 10 05:05 PM
Murphy NicoleHead of Pharm Ops and TechFeb 06 '26Option Exercise0.008,725021,016Feb 10 05:03 PM
Kramer RobinChief Financial OfficerFeb 06 '26Option Exercise0.005,003012,535Feb 10 05:02 PM
Keeney AdamHead of Corporate DevelopmentFeb 06 '26Option Exercise0.005,08006,875Feb 10 05:01 PM
Izzar RachidHead of Global Product Strat.Feb 06 '26Option Exercise0.006,889011,786Feb 10 05:00 PM
Grogan JaneHead of ResearchFeb 06 '26Option Exercise0.003,25804,642Feb 10 04:59 PM
Gregory GingerEVP, Human ResourcesFeb 06 '26Option Exercise0.007,183023,491Feb 10 04:58 PM
Godbout SeanChief Accounting OfficerFeb 06 '26Option Exercise0.001,07901,395Feb 10 04:56 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 06 '26Option Exercise0.009,046043,321Feb 10 04:55 PM
Singhal PriyaOfficerFeb 09 '26Proposed Sale199.832,660531,548Feb 09 10:14 AM
Singhal PriyaHead of DevelopmentJan 30 '26Option Exercise0.001,82907,601Feb 03 05:17 PM
Singhal PriyaHead of DevelopmentFeb 02 '26Sale179.30748134,1166,271Feb 03 05:17 PM
Singhal PriyaOfficerFeb 02 '26Proposed Sale179.30748134,116Feb 02 11:10 AM
Viehbacher ChristopherPresident and CEODec 01 '25Option Exercise0.007,040019,847Dec 03 04:42 PM
Grogan JaneHead of ResearchOct 31 '25Option Exercise0.0069502,128Nov 04 04:12 PM
Godbout SeanChief Accounting OfficerOct 02 '25Option Exercise0.00260503Oct 06 01:00 PM
Singhal PriyaHead of DevelopmentAug 29 '25Option Exercise0.001,66907,096Sep 02 05:56 PM
Singhal PriyaHead of DevelopmentSep 02 '25Sale133.5551769,0455,772Sep 02 05:56 PM
Singhal PriyaOfficerSep 02 '25Proposed Sale133.5551769,045Sep 02 12:54 PM
Izzar RachidHead of Global Product Strat.Jul 08 '25Sale135.002,223300,1056,330Jul 16 05:55 PM
Izzar RachidOfficerJul 08 '25Proposed Sale135.002,223300,105Jul 08 03:26 PM
Singhal PriyaHead of DevelopmentMay 19 '25Sale126.253,806480,5085,427May 20 04:05 PM
Singhal PriyaOfficerMay 19 '25Proposed Sale126.253,806480,508May 19 11:24 AM
Keeney AdamHead of Corporate DevelopmentMay 01 '25Option Exercise0.0093802,838May 05 04:19 PM
DORSA CAROLINEDirectorMay 02 '25Buy122.721,235151,55927,842May 05 04:17 PM
SHERWIN STEPHEN ADirectorMar 07 '25Sale150.028,7601,314,14211,318Mar 10 04:09 PM
STEPHEN A SHERWINDirectorMar 07 '25Proposed Sale147.378,7601,290,961Mar 07 04:18 PM
Last Close
Feb 13  •  04:00PM ET
116.81
Dollar change
+2.37
Percentage change
2.07
%
ILMN Illumina Inc daily Stock Chart
Index- P/E21.38 EPS (ttm)5.46 Insider Own2.81% Shs Outstand153.00M Perf Week-2.43%
Market Cap17.86B Forward P/E20.07 EPS next Y5.82 Insider Trans-0.00% Shs Float148.60M Perf Month-18.87%
Enterprise Value18.78B PEG1.83 EPS next Q1.07 Inst Own105.48% Short Float5.59% Perf Quarter-4.24%
Income850.00M P/S4.11 EPS this Y5.66% Inst Trans1.49% Short Ratio4.34 Perf Half Y16.70%
Sales4.34B P/B6.56 EPS next Y13.82% ROA13.13% Short Interest8.30M Perf YTD-10.94%
Book/sh17.80 P/C10.94 EPS next 5Y10.98% ROE33.36% 52W High155.53 -24.90% Perf Year14.77%
Cash/sh10.68 P/FCF19.18 EPS past 3/5Y- 4.22% ROIC18.09% 52W Low68.70 70.03% Perf 3Y-44.34%
Dividend Est.- EV/EBITDA16.12 Sales past 3/5Y-1.82% 6.02% Gross Margin67.08% Volatility3.27% 3.89% Perf 5Y-76.19%
Dividend TTM- EV/Sales4.33 EPS Y/Y TTM171.36% Oper. Margin20.59% ATR (14)5.39 Perf 10Y-15.78%
Dividend Ex-Date- Quick Ratio1.72 Sales Y/Y TTM-0.71% Profit Margin19.58% RSI (14)30.57 Recom2.46
Dividend Gr. 3/5Y- - Current Ratio2.08 EPS Q/Q85.56% SMA20-14.84% Beta1.49 Target Price135.32
Payout0.00% Debt/Eq0.94 Sales Q/Q5.07% SMA50-14.60% Rel Volume1.00 Prev Close114.44
Employees8600 LT Debt/Eq0.73 EarningsFeb 05 AMC SMA2008.29% Avg Volume1.91M Price116.81
IPOJul 28, 2000 Option/ShortYes / Yes EPS/Sales Surpr.8.70% 3.60% Trades Volume1,902,845 Change2.07%
Date Action Analyst Rating Change Price Target Change
Aug-12-25Downgrade Daiwa Securities Outperform → Neutral $94
Jul-11-25Downgrade Scotiabank Sector Outperform → Sector Perform $125
Mar-04-25Reiterated Citigroup Neutral $130 → $90
Feb-28-25Downgrade HSBC Securities Buy → Hold $100
Feb-10-25Downgrade Barclays Equal Weight → Underweight $130 → $100
Feb-07-25Downgrade TD Cowen Buy → Hold $177 → $140
Dec-11-24Downgrade Citigroup Buy → Neutral $190 → $165
Nov-12-24Resumed Morgan Stanley Equal-Weight $156
Oct-17-24Upgrade HSBC Securities Hold → Buy $180
Aug-28-24Upgrade Argus Hold → Buy
Feb-12-26 10:00AM
09:45AM
08:24AM
12:36AM
Feb-09-26 11:19AM
09:15AM Loading…
09:15AM
Feb-06-26 01:25PM
03:48AM
12:36AM
12:05AM
Feb-05-26 08:58PM
07:00PM
06:00PM
04:59PM
04:17PM
04:06PM Loading…
04:06PM
Feb-04-26 09:15AM
Feb-03-26 10:18PM
06:15PM
09:15AM
08:55AM
Feb-02-26 09:37AM
12:47AM
Jan-30-26 10:00AM
09:05AM
Jan-29-26 10:00AM
Jan-27-26 08:55AM
Jan-24-26 12:01PM
Jan-23-26 11:40AM
Jan-21-26 10:31PM
04:58PM Loading…
04:58PM
Jan-20-26 01:19PM
09:15AM
04:58AM
12:05AM
Jan-16-26 02:22AM
Jan-15-26 08:55AM
Jan-13-26 04:58PM
01:01PM
12:37PM
09:15AM
09:00AM
07:30AM
Jan-12-26 04:07PM
11:34AM
08:09AM
Jan-09-26 12:10PM
08:55AM
Jan-08-26 04:30PM
04:30PM
Jan-07-26 11:40AM
07:33AM
Jan-06-26 07:48PM
11:40AM
09:15AM
07:06AM
Jan-02-26 07:35AM
Dec-31-25 09:50AM
01:30AM
Dec-30-25 08:06AM
07:32AM
Dec-26-25 07:49AM
07:18AM
07:17AM
Dec-24-25 08:36AM
Dec-23-25 02:08PM
02:08PM
Dec-22-25 07:49AM
07:11AM
Dec-19-25 09:09AM
Dec-18-25 08:36AM
07:45AM
Dec-17-25 10:14AM
07:58AM
07:55AM
Dec-16-25 04:05PM
07:58AM
07:47AM
Dec-15-25 09:12AM
Dec-12-25 09:50AM
07:11AM
Dec-11-25 09:15AM
08:09AM
Dec-10-25 08:34AM
08:31AM
Dec-09-25 07:28AM
07:27AM
07:26AM
04:49AM
Dec-08-25 10:15AM
09:45AM
07:56AM
Dec-05-25 11:30AM
08:48AM
Dec-04-25 11:30AM
07:20AM
Dec-03-25 12:00PM
Nov-20-25 04:15PM
05:00AM
Nov-19-25 09:50AM
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gottlieb ScottDirectorFeb 09 '26Buy117.8120023,56212,723Feb 11 04:04 PM
Davies Scott MChief Legal OfficerDec 12 '25Sale136.0932343,95717,887Dec 16 05:00 PM
SCOTT DAVIESOfficerDec 12 '25Proposed Sale136.0932343,957Dec 12 04:09 PM
Wedel Christensen JakobSVP, Strategy/Corp DevelopmentDec 08 '25Sale129.2754970,96910,952Dec 09 04:15 PM
JAKOB WEDELOfficerDec 08 '25Proposed Sale129.2754970,969Dec 08 04:31 PM
ILLUMINA, INC.10% OwnerNov 17 '25Sale79.851,000,00079,850,0003,502,126Nov 18 09:33 PM
SCOTT DAVIESOfficerNov 12 '25Proposed Sale122.7932339,661Nov 12 04:05 PM
Gottlieb ScottDirectorNov 03 '25Buy122.1350061,06512,523Nov 05 04:05 PM
Dhingra AnkurSVP, Chief Financial OfficerMay 12 '25Buy81.216,100495,38124,906May 14 04:20 PM
Thaysen JacobChief Executive OfficerMay 12 '25Buy80.886,500525,73277,540May 14 04:18 PM
Thaysen JacobChief Executive OfficerMay 13 '25Buy80.845,850472,94283,390May 14 04:18 PM
JAKOB WEDEL CHRISTENSENOfficerMay 06 '25Proposed Sale77.2154942,388May 06 04:02 PM
ARNOLD FRANCESDirectorFeb 27 '25Proposed Sale93.4812011,218Feb 27 11:07 AM
JAKOB WEDELOfficerFeb 18 '25Proposed Sale100.0046046,000Feb 18 04:22 PM
PATRICIA L LECKMANOfficerFeb 18 '25Proposed Sale100.001,756175,600Feb 18 04:08 PM
Last Close
Feb 13  •  04:00PM ET
128.20
Dollar change
+2.09
Percentage change
1.66
%
DUK Duke Energy Corp daily Stock Chart
IndexS&P 500 P/E20.31 EPS (ttm)6.31 Insider Own0.17% Shs Outstand778.00M Perf Week5.20%
Market Cap99.70B Forward P/E17.93 EPS next Y7.15 Insider Trans-1.36% Shs Float776.41M Perf Month8.02%
Enterprise Value192.47B PEG2.72 EPS next Q1.77 Inst Own69.47% Short Float1.73% Perf Quarter3.47%
Income4.91B P/S3.09 EPS this Y6.22% Inst Trans0.29% Short Ratio3.53 Perf Half Y3.17%
Sales32.24B P/B1.96 EPS next Y6.69% ROA2.57% Short Interest13.44M Perf YTD9.38%
Book/sh65.38 P/C406.92 EPS next 5Y6.58% ROE9.74% 52W High130.03 -1.41% Perf Year12.51%
Cash/sh0.32 P/FCF- EPS past 3/5Y25.82% 29.72% ROIC3.69% 52W Low110.51 16.01% Perf 3Y28.15%
Dividend Est.4.40 (3.43%) EV/EBITDA12.92 Sales past 3/5Y3.87% 6.20% Gross Margin31.56% Volatility2.23% 1.72% Perf 5Y42.73%
Dividend TTM4.24 (3.31%) EV/Sales5.97 EPS Y/Y TTM11.06% Oper. Margin26.61% ATR (14)2.17 Perf 10Y68.15%
Dividend Ex-DateFeb 13, 2026 Quick Ratio0.33 Sales Y/Y TTM6.19% Profit Margin15.22% RSI (14)74.27 Recom2.04
Dividend Gr. 3/5Y1.97% 2.01% Current Ratio0.55 EPS Q/Q-3.13% SMA205.59% Beta0.50 Target Price134.40
Payout66.75% Debt/Eq1.75 Sales Q/Q7.85% SMA508.05% Rel Volume1.46 Prev Close126.11
Employees26413 LT Debt/Eq1.57 EarningsFeb 10 BMO SMA2006.39% Avg Volume3.80M Price128.20
IPOJul 12, 1961 Option/ShortYes / Yes EPS/Sales Surpr.0.94% 6.89% Trades Volume5,565,921 Change1.66%
Date Action Analyst Rating Change Price Target Change
Oct-28-25Resumed RBC Capital Mkts Sector Perform $143
Oct-28-25Initiated Wells Fargo Equal Weight $126
Oct-22-25Initiated BTIG Research Buy $150
Oct-16-25Initiated TD Cowen Buy $143
Oct-07-25Initiated Evercore ISI Outperform $143
Oct-03-25Upgrade Scotiabank Sector Perform → Sector Outperform $137
Sep-26-25Downgrade Jefferies Buy → Hold $134
Jun-25-25Upgrade Goldman Neutral → Buy $132
Jun-13-25Initiated Raymond James Mkt Perform
Oct-22-24Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Feb-14-26 05:26AM
Feb-13-26 10:29AM
12:01AM
Feb-12-26 06:26PM
10:57AM
10:03AM Loading…
10:03AM
10:02AM
10:00AM
08:21AM
04:00AM
Feb-11-26 12:25AM
Feb-10-26 10:07PM
04:04PM
09:03AM
08:43AM
07:15AM Loading…
07:15AM
07:00AM
06:10AM
Feb-09-26 11:30AM
Feb-08-26 05:34AM
Feb-06-26 05:50PM
12:39PM
08:37AM
Feb-05-26 12:59PM
10:23AM
Feb-04-26 12:29PM
10:00AM
09:00AM
Feb-03-26 10:00AM
08:41AM
07:59AM Loading…
07:59AM
Feb-02-26 06:00PM
01:30PM
01:30PM
11:06AM
Feb-01-26 03:18PM
10:00AM
09:32AM
Jan-30-26 10:30AM
09:41AM
Jan-29-26 10:38PM
06:38PM
10:45AM
08:29AM
Jan-28-26 12:52PM
06:00AM
Jan-27-26 03:53PM
02:47PM
Jan-26-26 02:52PM
03:42AM
Jan-25-26 04:39PM
Jan-24-26 09:52AM
07:25AM
Jan-23-26 10:08AM
Jan-22-26 06:00PM
09:13AM
Jan-21-26 09:16AM
09:00AM
04:54AM
Jan-19-26 08:54AM
Jan-16-26 05:50PM
10:12AM
09:23AM
07:55AM
Jan-15-26 11:09AM
09:40AM
Jan-14-26 09:25PM
06:00PM
04:14PM
12:52PM
11:00AM
10:04AM
07:10AM
Jan-12-26 01:01PM
Jan-08-26 12:12PM
11:00AM
10:30AM
09:00AM
Jan-07-26 06:00PM
12:45PM
Jan-06-26 01:49PM
12:30PM
Jan-04-26 05:27PM
Jan-02-26 10:41AM
09:10AM
Dec-31-25 09:05AM
Dec-30-25 10:50PM
08:58AM
Dec-29-25 01:30PM
10:59AM
08:45AM
Dec-24-25 11:19AM
09:00AM
Dec-22-25 11:29AM
09:34AM
08:30AM
Dec-21-25 09:31AM
Dec-20-25 03:00PM
10:21AM
Dec-19-25 05:50PM
Duke Energy Corp. engages in the distribution of natural gas and energy-related services. It operates through the following segments: Electric Utilities and Infrastructure, Gas Utilities and Infrastructure, and Other. The Electric Utilities and Infrastructure segment conducts operations in regulated electric utilities in the Carolinas, Florida and the Midwest. The Gas Utilities and Infrastructure segment focuses on Piedmont, natural gas local distribution companies in Ohio and Kentucky, and natural gas storage and midstream pipeline investments. The Other segment includes interest expense on holding company debt, unallocated corporate costs, and Bison which is a wholly owned captive insurance company. The company was founded on April 30, 1904 and is headquartered in Charlotte, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Renjel Louis E.EVP&CEO DEF&MW&ChiefCorpAffOffFeb 12 '26Sale127.676,800868,15622,007Feb 13 04:33 PM
Renjel Louis E.OfficerFeb 12 '26Proposed Sale127.676,800868,157Feb 12 02:32 PM
Glenn Robert AlexanderEVP & Chief Legal OfficerNov 19 '25Sale123.808,2001,015,16011,367Nov 20 04:33 PM
Renjel Louis E.EVP&CEO DEF&MW&ChiefCorpAffOffNov 18 '25Sale125.65800100,52020,332Nov 19 04:09 PM
Glenn Robert AlexanderOfficerNov 19 '25Proposed Sale123.808,2001,015,160Nov 19 09:42 AM
Renjel Louis E.OfficerNov 18 '25Proposed Sale125.65800100,520Nov 18 11:31 AM
JANSON JULIA SAssociated to AffiliateAug 25 '25Proposed Sale124.1410,0001,241,400Aug 25 04:04 PM
Weintraub Alexander J.SVP, Chief Customer OfficerAug 19 '25Sale121.6440048,6567,860Aug 21 04:25 PM
Titone Bonnie B.SVP, Chief Admin OfficerAug 20 '25Sale124.382,000248,76419,608Aug 21 04:23 PM
Titone Bonnie B.OfficerAug 20 '25Proposed Sale124.382,000248,764Aug 20 02:29 PM
Weintraub Alexander J.OfficerAug 19 '25Proposed Sale121.6440048,656Aug 19 10:20 AM
Gillespie Thomas Preston Jr.EVP-Chf Gen Off-Entrp Op ExcelAug 12 '25Sale124.266,700832,54246,422Aug 13 04:53 PM
Gillespie Thomas Preston Jr.OfficerAug 12 '25Proposed Sale124.266,700832,543Aug 12 04:06 PM
Renjel Louis E.EVP&CEO Duke Energy FL&MidwestAug 07 '25Sale125.561,580198,37821,132Aug 08 03:25 PM
MCKEE E MARIEDirectorAug 07 '25Sale124.881,610201,0571Aug 08 03:24 PM
Renjel Louis E.OfficerAug 07 '25Proposed Sale125.561,580198,378Aug 07 01:07 PM
MCKEE E MARIEDirectorAug 07 '25Proposed Sale124.881,610201,057Aug 07 12:48 PM
Ghartey-Tagoe KodwoEVP, CLO & Corp SecFeb 28 '25Sale117.109,0071,054,72045,709Mar 03 04:35 PM
JANSON JULIA SEVP&CEO, Duke Energy CarolinasFeb 26 '25Sale116.0910,0001,160,86669,768Feb 28 04:21 PM
Ghartey-Tagoe KodwoOfficerFeb 28 '25Proposed Sale117.109,0071,054,720Feb 28 10:28 AM
JANSON JULIA SOfficerFeb 26 '25Proposed Sale116.0910,0001,160,866Feb 26 10:37 AM
Renjel Louis E.EVP, Chief Corporate AffairsFeb 18 '25Sale111.494,870542,96920,161Feb 20 04:20 PM
Renjel Louis E.OfficerFeb 18 '25Proposed Sale111.494,870542,970Feb 18 12:38 PM
Last Close
Feb 13  •  04:00PM ET
11.87
Dollar change
+0.25
Percentage change
2.15
%
NTLA Intellia Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-4.27 Insider Own5.12% Shs Outstand115.79M Perf Week-3.34%
Market Cap1.37B Forward P/E- EPS next Y-3.62 Insider Trans1.30% Shs Float109.90M Perf Month-1.25%
Enterprise Value961.83M PEG- EPS next Q-0.95 Inst Own86.70% Short Float41.24% Perf Quarter25.08%
Income-445.81M P/S23.90 EPS this Y24.23% Inst Trans7.47% Short Ratio9.05 Perf Half Y8.90%
Sales57.53M P/B1.84 EPS next Y9.09% ROA-42.49% Short Interest45.32M Perf YTD32.04%
Book/sh6.46 P/C2.69 EPS next 5Y33.19% ROE-52.11% 52W High28.25 -57.98% Perf Year23.13%
Cash/sh4.41 P/FCF- EPS past 3/5Y-11.59% -20.04% ROIC-54.43% 52W Low5.90 101.19% Perf 3Y-71.27%
Dividend Est.- EV/EBITDA- Sales past 3/5Y20.53% 6.07% Gross Margin78.27% Volatility6.46% 9.29% Perf 5Y-82.62%
Dividend TTM- EV/Sales16.72 EPS Y/Y TTM21.66% Oper. Margin-820.86% ATR (14)1.02 Perf 10Y-
Dividend Ex-Date- Quick Ratio6.21 Sales Y/Y TTM33.52% Profit Margin-774.94% RSI (14)47.92 Recom2.33
Dividend Gr. 3/5Y- - Current Ratio6.21 EPS Q/Q31.56% SMA20-9.14% Beta2.13 Target Price21.94
Payout- Debt/Eq0.13 Sales Q/Q51.27% SMA507.27% Rel Volume0.52 Prev Close11.62
Employees403 LT Debt/Eq0.09 EarningsNov 06 AMC SMA200-1.00% Avg Volume5.01M Price11.87
IPOMay 06, 2016 Option/ShortYes / Yes EPS/Sales Surpr.8.48% -0.94% Trades Volume2,626,165 Change2.15%
Date Action Analyst Rating Change Price Target Change
Nov-12-25Downgrade Wolfe Research Outperform → Peer Perform
Nov-11-25Downgrade Evercore ISI Outperform → In-line $8
Nov-07-25Downgrade JP Morgan Neutral → Underweight $5
Oct-28-25Downgrade RBC Capital Mkts Outperform → Sector Perform $14
Oct-28-25Downgrade Bernstein Outperform → Mkt Perform
Oct-27-25Downgrade William Blair Outperform → Mkt Perform
Oct-27-25Downgrade Guggenheim Buy → Neutral
Oct-06-25Upgrade Citizens JMP Mkt Perform → Mkt Outperform $33
Apr-21-25Upgrade Wolfe Research Peer Perform → Outperform $21
Mar-05-25Initiated H.C. Wainwright Buy $30
Feb-15-26 08:41AM
Feb-09-26 08:02AM
Feb-06-26 07:30AM
Feb-04-26 07:27PM
Feb-02-26 09:37AM
08:25AM Loading…
08:25AM
Jan-28-26 09:45AM
07:35AM
06:33AM
Jan-27-26 04:04PM
01:03PM
08:31AM
08:00AM
06:59AM
Jan-22-26 08:47PM
01:27PM Loading…
Jan-19-26 01:27PM
Jan-15-26 10:56AM
Jan-14-26 09:30AM
Jan-07-26 07:30AM
Jan-05-26 12:23PM
10:58AM
Jan-02-26 04:01PM
Dec-31-25 01:33PM
09:32AM
06:26AM
Dec-30-25 07:35AM
Dec-29-25 09:50AM
Dec-05-25 04:01PM
Dec-04-25 01:41PM
Dec-02-25 08:00AM
09:59AM Loading…
Nov-28-25 09:59AM
Nov-27-25 08:15AM
Nov-25-25 08:39AM
Nov-21-25 10:19AM
Nov-18-25 08:48AM
04:45AM
Nov-15-25 09:35AM
Nov-14-25 08:58AM
Nov-13-25 09:00AM
Nov-12-25 09:45AM
Nov-11-25 07:30AM
Nov-10-25 03:17PM
01:19PM
Nov-08-25 05:28PM
05:13PM
Nov-07-25 05:09PM
04:14PM
10:55AM
09:56AM
08:45AM
Nov-06-25 05:20PM
04:00PM
Nov-05-25 11:35AM
11:27AM
Nov-04-25 10:41AM
10:28AM
10:26AM
Nov-03-25 10:11AM
Nov-02-25 09:25AM
Oct-31-25 01:44PM
10:00AM
Oct-30-25 07:14PM
06:54AM
Oct-29-25 06:05PM
Oct-28-25 12:43PM
09:42AM
Oct-27-25 12:03PM
08:25AM
08:00AM
07:30AM
Oct-21-25 12:56PM
Oct-20-25 09:25AM
09:16AM
Oct-12-25 09:45AM
Oct-09-25 09:23AM
04:59AM
Oct-08-25 12:00PM
10:22AM
09:55AM
09:40AM
Oct-07-25 09:45AM
Oct-06-25 08:07AM
Oct-03-25 04:01PM
Oct-01-25 10:47AM
Sep-25-25 01:57PM
09:52AM
Sep-22-25 09:09AM
07:30AM
Sep-19-25 12:24PM
09:20AM
Sep-18-25 07:30AM
Sep-11-25 03:45AM
Sep-10-25 11:30AM
Sep-02-25 03:46PM
09:03AM
Aug-29-25 10:22AM
Aug-21-25 11:15AM
10:59AM
Aug-12-25 11:40AM
Aug-11-25 07:43AM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEONARD JOHN MPresident and CEOJan 05 '26Sale9.2134,146314,4851,013,339Jan 07 04:05 PM
Schultes Birgit CEVP, Chief Scientific OfficerJan 05 '26Sale9.218,50878,35998,533Jan 07 04:05 PM
BASTA JAMESEVP, General CounselJan 05 '26Sale9.2110,39795,756101,528Jan 07 04:05 PM
Cohen Fred EDirectorJan 05 '26Buy9.35150,0001,402,500207,453Jan 07 04:05 PM
Lebwohl DavidEVP, Chief Medical OfficerJan 05 '26Sale9.2111,903109,627121,249Jan 07 04:04 PM
Clark ElianaEVP, Chief Technical OfficerJan 05 '26Sale9.219,51587,63387,118Jan 07 04:03 PM
Dulac Edward J IIIEVP, Chief Financial OfficerJan 05 '26Sale9.216,37958,75199,683Jan 07 04:02 PM
Dube Michael PVP, Chief Accounting OfficerJan 05 '26Sale9.212,98927,52952,277Jan 07 04:01 PM
LEONARD JOHN MPresident and CEODec 11 '25Option Exercise6.8349,959341,2201,127,074Dec 12 04:09 PM
LEONARD JOHN MPresident and CEODec 12 '25Option Exercise6.838,55758,4441,047,485Dec 12 04:09 PM
LEONARD JOHN MPresident and CEODec 11 '25Sale9.4988,146836,3841,038,928Dec 12 04:09 PM
LEONARD JOHN MOfficerDec 11 '25Proposed Sale9.3388,146822,402Dec 11 04:11 PM
Schultes Birgit CEVP, Chief Scientific OfficerOct 01 '25Sale17.3831539105,184Oct 03 05:13 PM
Dube Michael PVP, Chief Accounting OfficerOct 01 '25Sale17.381,87132,51855,266Oct 03 05:13 PM
CHASE WILLIAM JDirectorAug 20 '25Buy10.03100,0001,003,000134,693Aug 22 04:30 PM
Dulac Edward J IIIEVP, Chief Financial OfficerJul 23 '25Sale14.027,462104,617106,062Jul 25 04:05 PM
Clark ElianaEVP, Chief Technical OfficerJul 01 '25Sale9.821,02210,03695,369Jul 03 04:11 PM
Dube Michael PVP, Chief Accounting OfficerJul 02 '25Sale9.952,50324,90557,137Jul 03 04:07 PM
GOODMAN JESSEDirectorJun 30 '25Sale9.561,54714,78925,906Jul 02 05:50 PM
GOODMAN JESSEDirectorJul 01 '25Sale9.231,54714,27924,359Jul 02 05:50 PM
Bhanji MunaDirectorApr 29 '25Sale8.502652,25219,203May 01 04:24 PM
Clark ElianaEVP, Chief Technical OfficerMar 04 '25Sale8.996796,10495,369Mar 04 04:43 PM
BASTA JAMESEVP, General CounselMar 04 '25Sale8.992,57223,122111,925Mar 04 04:21 PM